|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 16/14/16 | CHUGAI PHARMACEUTICAL : Roche's $8 billion InterMune buy not a signal for more big deals | RE |
| 04/14/04 | Roche : rules out mega deals, open to smaller ones - paper | RE |
Executive Committee: InterMune Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Mark Thompson
CEO | Chief Executive Officer | 57 | - |
| Chief Tech/Sci/R&D Officer | 71 | 01/04/2002 | |
Carla Fiankan
LAW | General Counsel | - | 01/08/2011 |
Company details: InterMune Inc
Other Biotechnology & Medical Research
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.62% | -1.87% | +46.31% | +56.99% | 6.38TCr | |
| +0.35% | +3.20% | +14.92% | +84.55% | 5.64TCr | |
| +0.53% | +1.96% | +15.37% | +106.81% | 5.46TCr | |
| -2.81% | -4.31% | +23.50% | +50.90% | 4.41TCr | |
| -0.33% | -1.93% | +20.15% | +98.45% | 4.21TCr | |
| +0.55% | +2.31% | +224.97% | +942.56% | 4.1TCr | |
| +3.27% | +47.96% | +112.67% | +96.48% | 3.49TCr | |
| +1.22% | -1.44% | +14.89% | +47.15% | 3.28TCr | |
| +0.89% | +20.55% | -42.03% | +373.03% | 2.47TCr | |
| Average | +0.34% | +7.54% | +47.86% | +206.32% | 4.38TCr | |
| Weighted average by Cap. | +0.18% | +5.44% | +48.50% | +186.13% |
- Stock Market
- Stocks
- Stock
- Company InterMune Inc
Select your edition
All financial news and data tailored to specific country editions
